CERS2 and urinary bladder cancer: Although the expression of LASS2 was not associated with the prognosis of total bladder cancer patients, we found that patients with low expression of LASS2 had a worse prognosis in a subgroup analysis of those receiving cisplatin-based chemotherapy.